HK1193568A1 - New abuse-resistant pharmaceutical composition for the treatment of opioid dependence - Google Patents

New abuse-resistant pharmaceutical composition for the treatment of opioid dependence

Info

Publication number
HK1193568A1
HK1193568A1 HK14106999.2A HK14106999A HK1193568A1 HK 1193568 A1 HK1193568 A1 HK 1193568A1 HK 14106999 A HK14106999 A HK 14106999A HK 1193568 A1 HK1193568 A1 HK 1193568A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pharmaceutical composition
opioid dependence
resistant pharmaceutical
new abuse
Prior art date
Application number
HK14106999.2A
Other languages
English (en)
Chinese (zh)
Inventor
Andreas Fischer
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1193568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of HK1193568A1 publication Critical patent/HK1193568A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
HK14106999.2A 2011-09-19 2014-07-09 New abuse-resistant pharmaceutical composition for the treatment of opioid dependence HK1193568A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536180P 2011-09-19 2011-09-19
PCT/GB2012/052303 WO2013041851A1 (en) 2011-09-19 2012-09-18 New abuse-resistant pharmaceutical composition for the treatment of opioid dependence

Publications (1)

Publication Number Publication Date
HK1193568A1 true HK1193568A1 (en) 2014-09-26

Family

ID=47046639

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14106999.2A HK1193568A1 (en) 2011-09-19 2014-07-09 New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
HK15111331.8A HK1210438A1 (en) 2011-09-19 2015-11-17 Sublingual abuse-resistant tablets comprising buprenorphine and naloxone

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15111331.8A HK1210438A1 (en) 2011-09-19 2015-11-17 Sublingual abuse-resistant tablets comprising buprenorphine and naloxone

Country Status (31)

Country Link
US (15) US20130071477A1 (xx)
EP (3) EP3939569A1 (xx)
JP (2) JP6210988B2 (xx)
KR (1) KR102078044B1 (xx)
CN (1) CN103813785B (xx)
AU (1) AU2012311293B2 (xx)
BR (1) BR112014006356B1 (xx)
CA (1) CA2834327C (xx)
CL (1) CL2014000575A1 (xx)
CO (1) CO6960541A2 (xx)
CY (2) CY1116270T1 (xx)
DK (2) DK2915525T3 (xx)
EA (1) EA029507B1 (xx)
ES (2) ES2538460T3 (xx)
HK (2) HK1193568A1 (xx)
HR (2) HRP20211539T1 (xx)
HU (1) HUE056309T2 (xx)
IL (1) IL230528B (xx)
LT (1) LT2915525T (xx)
ME (1) ME02153B (xx)
MX (1) MX361757B (xx)
MY (1) MY185284A (xx)
PE (1) PE20141198A1 (xx)
PL (2) PL2706986T3 (xx)
PT (2) PT2706986E (xx)
RS (2) RS62505B1 (xx)
SG (1) SG2014009401A (xx)
SI (2) SI2706986T1 (xx)
SM (1) SMT201500126B (xx)
WO (1) WO2013041851A1 (xx)
ZA (1) ZA201400501B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141198A1 (es) 2011-09-19 2014-10-05 Orexo Ab Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides
US20140280531A1 (en) * 2013-03-13 2014-09-18 Xin Liu Object ranking and recommendations within a social network
EP2983668A4 (en) * 2013-04-08 2017-01-11 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
EP2886103A1 (en) * 2013-12-23 2015-06-24 Hexal AG Pharmaceutical orodispersible film comprising buprenorphine particles with a particular size
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP2017519803A (ja) * 2014-07-08 2017-07-20 インシス・ファーマ・インコーポレーテッド 舌下ナロキソンスプレー
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
CA3033897C (en) * 2016-08-17 2024-03-26 Insys Development Company, Inc. Liquid naloxone spray
CN110325178B (zh) 2016-12-26 2022-05-13 盐野义制药株式会社 改善含量均一性的制剂的制造方法
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
MX2020003697A (es) * 2017-10-20 2020-08-13 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
WO2019099679A1 (en) * 2017-11-15 2019-05-23 The Regents Of The University Of California Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain
CN111757728A (zh) 2018-03-11 2020-10-09 纳诺洛吉卡股份公司 用于压缩的药物剂型的多孔二氧化硅颗粒
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
MA55719A (fr) * 2019-04-18 2022-02-23 Chiesi Farm Spa Procédé de traitement du syndrome de sevrage des opioïdes néonatal
US11571414B2 (en) 2019-09-06 2023-02-07 Eric Dwayne Ford Methods of treating respiratory illnesses, alleviating inflammation and visceral pain, and alleviating opioid addiction while suppressing withdrawal symptoms
MX2022010800A (es) * 2020-03-11 2022-09-27 Purdue Pharma Lp Composiciones y metodos para la administracion de naloxona.

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
JPS5138412A (en) 1974-09-24 1976-03-31 Nippon Kayaku Kk Kokoseizai no seiho
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
AU8533582A (en) 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4529583A (en) 1983-03-07 1985-07-16 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
FR2562313B1 (fr) 1984-04-03 1989-04-07 Cogema Procede de decontamination en uranium et en radium de solutions uraniferes acides par addition d'un sel d'aluminium
GB2162061B (en) 1984-05-03 1988-11-16 Bibhuti B Bardhan Controlled time release therapeutic composition having means for counteracting overdosage
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4885173A (en) 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
FR2582513B1 (fr) 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
SE8800080L (sv) 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US4981468A (en) 1989-02-17 1991-01-01 Eli Lilly And Company Delivery device for orally administered therapeutic agents
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
CA2070061C (en) 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5362496A (en) 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5547878A (en) 1993-11-02 1996-08-20 Kell; Michael Method of monitoring patient compliance with medications prescriptions
US5856493A (en) 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2259418A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6217000B1 (en) 1996-10-25 2001-04-17 The Boeing Company Composite fabrication method and tooling to improve part consolidation
GB9710726D0 (en) 1997-05-23 1997-07-16 Nycomed Imaging As Compound
IL128043A (en) 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
TR200001828T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
US6228469B1 (en) 1999-09-07 2001-05-08 Corning Incorporated Protective coating on metal
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CN101703777B (zh) 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
US6897123B2 (en) 2001-03-05 2005-05-24 Agityne Corporation Bonding of parts with dissimilar thermal expansion coefficients
EP1389092B1 (en) 2001-05-11 2006-11-15 Endo Pharmaceuticals Inc. Abuse-resistant opioid dosage form
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
PT1416842E (pt) 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20030125347A1 (en) 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
WO2004054511A2 (en) 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
SI1587514T1 (sl) 2003-01-31 2006-10-31 Orexo Ab Hitro ucinkujoc farmacevtski sestavek
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
WO2005117838A1 (en) * 2004-06-02 2005-12-15 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and derivatives
US20060051413A1 (en) 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
WO2006103418A1 (en) 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of pain
US8021638B2 (en) 2005-03-31 2011-09-20 Touchstone Research Laboratory, Ltd Carbon foam and high density carbon foam composite tooling
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
JP2007321063A (ja) * 2006-06-01 2007-12-13 Sumitomo Chemical Co Ltd 樹脂粒子の分離方法
US20100233257A1 (en) 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
KR101230804B1 (ko) 2006-07-21 2013-02-08 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
CN1943575A (zh) 2006-10-24 2007-04-11 岳振江 滥用潜力低的复方盐酸丁丙诺啡盐酸纳洛酮舌下片
WO2008068471A1 (en) * 2006-12-04 2008-06-12 Orexo Ab New non-abusable pharmaceutical composition comprising opioids
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CN101631549B (zh) * 2007-03-15 2012-08-22 东洋纺织株式会社 贴附于口腔粘膜的丁丙诺非制剂的制造方法
GB2450117A (en) 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
GB0712535D0 (en) 2007-06-28 2007-08-08 Airbus Uk Ltd Method for forming composite components and tool for use therein
US7968021B2 (en) 2007-07-31 2011-06-28 The Boeing Company Coefficient of thermal expansion control structure
US20090263476A1 (en) 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US20090266870A1 (en) 2008-04-23 2009-10-29 The Boeing Company Joined composite structures with a graded coefficient of thermal expansion for extreme environment applications
JP2010043236A (ja) * 2008-07-17 2010-02-25 Sekisui Chem Co Ltd タンニン系接着剤、及びそれを用いた木質系複合材料
US20100291160A1 (en) 2009-05-13 2010-11-18 Carver David R Pharmaceutical system for trans-membrane delivery
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US8269514B2 (en) 2009-08-25 2012-09-18 Formfactor, Inc. Method and apparatus for multilayer support substrate
JP5371050B2 (ja) * 2009-11-06 2013-12-18 住友精化株式会社 ジボランの製造方法
PE20141198A1 (es) 2011-09-19 2014-10-05 Orexo Ab Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides
ME02644B (me) 2012-05-02 2017-06-20 Orexo Ab Novi preparati alfentanila za tretman akutnog bola

Also Published As

Publication number Publication date
US20150196492A1 (en) 2015-07-16
ZA201400501B (en) 2017-06-28
EP2706986B1 (en) 2015-03-04
US11020387B2 (en) 2021-06-01
US20130071477A1 (en) 2013-03-21
LT2915525T (lt) 2021-09-27
CY1124764T1 (el) 2022-07-22
HRP20211539T1 (hr) 2021-12-24
PE20141198A1 (es) 2014-10-05
HUE056309T2 (hu) 2022-02-28
EA029507B1 (ru) 2018-04-30
AU2012311293B2 (en) 2014-02-20
US20210008061A1 (en) 2021-01-14
NZ709502A (en) 2017-01-27
US20180104235A1 (en) 2018-04-19
JP2017171687A (ja) 2017-09-28
CA2834327C (en) 2017-05-30
PL2706986T3 (pl) 2015-08-31
US9439900B2 (en) 2016-09-13
PL2915525T3 (pl) 2022-01-17
BR112014006356B1 (pt) 2022-01-18
ES2887104T3 (es) 2021-12-21
US20170246161A1 (en) 2017-08-31
IL230528A0 (en) 2014-03-31
DK2706986T3 (en) 2015-06-01
ME02153B (me) 2015-10-20
US20190054080A1 (en) 2019-02-21
MX2014002556A (es) 2014-10-06
US20160375010A1 (en) 2016-12-29
US20150238482A1 (en) 2015-08-27
BR112014006356A2 (pt) 2017-04-04
IL230528B (en) 2019-06-30
US20210030748A1 (en) 2021-02-04
US20150297583A1 (en) 2015-10-22
SMT201500126B (it) 2015-07-09
SI2706986T1 (sl) 2015-05-29
MY185284A (en) 2021-04-30
AU2012311293A1 (en) 2013-05-02
CO6960541A2 (es) 2014-05-30
SI2915525T1 (sl) 2022-01-31
EP2915525A1 (en) 2015-09-09
CA2834327A1 (en) 2013-03-28
KR102078044B1 (ko) 2020-02-17
US10874661B2 (en) 2020-12-29
KR20140075682A (ko) 2014-06-19
PT2706986E (pt) 2015-07-07
WO2013041851A1 (en) 2013-03-28
CN103813785A (zh) 2014-05-21
NZ618120A (en) 2015-10-30
JP6210988B2 (ja) 2017-10-11
MX361757B (es) 2018-12-13
RS62505B1 (sr) 2021-11-30
US20210008062A1 (en) 2021-01-14
DK2915525T3 (en) 2021-08-23
EP2915525B1 (en) 2021-08-11
US8940330B2 (en) 2015-01-27
ES2538460T3 (es) 2015-06-22
PT2915525T (pt) 2021-09-15
EP2706986A1 (en) 2014-03-19
SG2014009401A (en) 2014-05-29
HRP20150369T1 (hr) 2015-05-08
CN103813785B (zh) 2017-02-15
US10946010B2 (en) 2021-03-16
US20180042920A1 (en) 2018-02-15
US20200397780A1 (en) 2020-12-24
EP3939569A1 (en) 2022-01-19
HK1210438A1 (en) 2016-04-22
US11020388B2 (en) 2021-06-01
CL2014000575A1 (es) 2014-08-01
CY1116270T1 (el) 2017-02-08
JP2014526496A (ja) 2014-10-06
US11433066B2 (en) 2022-09-06
US20140023704A1 (en) 2014-01-23
RS53995B1 (en) 2015-10-30
EA201400246A1 (ru) 2014-05-30
US20140212496A1 (en) 2014-07-31
US9259421B2 (en) 2016-02-16

Similar Documents

Publication Publication Date Title
HK1193568A1 (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
AP3864A (en) Pharmaceutical composition
IL230010B (en) Inhalable pharmaceutical ingredients
PL3378862T3 (pl) Dihydropirymidynoizochinolinony i ich kompozycie farmaceutyczne do leczenia stwardnienia rozsianego
SG11201400580VA (en) Pharmaceutical composition for inhalation
GB201118232D0 (en) Pharmaceutical composition
SI2691083T1 (sl) Farmacevtski sestavek sitagliptina
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
IL231622B (en) A pharmaceutical preparation for the treatment of stubbornness
HK1189158A1 (en) Pharmaceutical composition
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
EP2711010A4 (en) PHARMACEUTICAL COMPOSITION
HUP1100444A2 (en) Pharmaceutical composition
HUP1100534A2 (en) Pharmaceutical composition for the treatment of muscle atrophy
HUP1100445A2 (en) Pharmaceutical composition
PT2812351T (pt) Composição farmacêutica para o tratamento de esclerose múltipla
AU2011900519A0 (en) Drug compositions for the treatment of insomnia
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
GB201301179D0 (en) Pharmaceutical composition comprising opioid analgesic
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds